| Literature DB >> 33732668 |
Muhammad Bakr Ghbeis1, Christina J Vander Pluym2, Ravi Ram Thiagarajan1.
Abstract
Ventricular assist devices (VAD) are used more in children. Safe and effective anticoagulation is required for successful management of children supported with ventricular assist devices. Developmental hemostasis, device hemocompatibility, plastic to body ratio, surgical variable techniques, lack of knowledge on pharmacokinetics of anticoagulants, and wide variability in anticoagulation protocols have all contributed to increased incidence of bleeding and thromboembolic complications. New collaborative learning networks, such as the ACTION network, provide opportunities to define best practices, optimize, and reduce anticoagulation related adverse events. ACTION was established Dec 2017. It consists of expert clinicians in heart failure, as well as researchers, parents, and patients, with goals to improve outcomes, share data, improve education and standard practice for children with heart failure (, n.d). Changes in pediatric VAD anticoagulation strategy from using mainly heparin to DTI such as bivalirudin have helped reduce bleeding and clotting complications.Entities:
Keywords: TEG-PM; anticoagulation; bivalirudin; bleeding; hemostasis; heparin; thrombosis; ventricular assistance device
Year: 2021 PMID: 33732668 PMCID: PMC7959853 DOI: 10.3389/fped.2021.625632
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418